Please login to the form below

Not currently logged in


This page shows the latest Otezla news and features for those working in and with pharma, biotech and healthcare.

AbbVie, Amgen and Takeda team up for joint COVID-19 trial

AbbVie, Amgen and Takeda team up for joint COVID-19 trial

19. The I-SPY COVID-19 trial will evaluate the safety and efficacy of AbbVie’s experimental CCR2 and CCR5 inhibitor cenicriviroc, Amgen’s psoriasis treatment Otezla (apremilast) and Takeda’s

Latest news

More from news
Approximately 10 fully matching, plus 28 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Infographic: RA Perceptions

    The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’s Otezla (apremilast) and Pfizer’s Xeljanz (tofacitinib), which both offer a new oral alternative ... Of the physicians who were familiar with

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....
The concordance conundrum: creating space for open dialogue
Growing numbers of patients want a partnership model with their HCP, whereby both parties are equally involved in the decision-making process. This model has been linked with an increase in...